The US Food and Drug Administration has granted its stamp of approval to Thermo Fisher Scientific’s Oncomine Dx Target for use in helping to identify patients who might benefit from treatment with Eli Lilly and Company drug Retevmo (selpercatinib).
The test identifies patients who have RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced...